Reports for APOTEX INC
Formerly known as AA PHARMA INC
Company Name
APOTEX INC
Shortage reports
Actual shortage:
220 (7%)
Anticipated shortage:
0 (0%)
Avoided shortage:
10 (0%)
Resolved:
3124 (93%)
3354
Discontinuation Reports
To be discontinued:
26 (7%)
Discontinued:
343 (93%)
Reversed:
0 (0%)
369
145 (4%)
73 (30%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2021-01-29 | 2021-05-03 | 132727 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2021-06-25 | 2021-07-19 | 141537 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2018-12-12 | 2018-12-27 | 69315 |
| APO-NAPROXEN | 375MG | TABLET | Resolved | 2018-02-26 | 2018-07-18 | 41142 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2025-03-07 | 2025-03-14 | 252148 |
| APO-NAPROXEN | 375MG | TABLET | Resolved | 2021-02-05 | 2021-03-30 | 133385 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2023-06-16 | 2023-08-18 | 195063 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2024-10-31 | 2025-02-07 | 241688 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2018-11-30 | 2019-05-24 | 68231 |
| APO-NAPROXEN | 375MG | TABLET | Resolved | 2018-11-30 | 2018-12-21 | 68228 |
| APO-NAPROXEN | 250MG | TABLET | Resolved | 2021-04-23 | 2021-06-28 | 137962 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2024-03-15 | 2024-06-21 | 222478 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2018-03-27 | 2018-04-10 | 44111 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2020-09-09 | 2020-10-05 | 123954 |
| APO-NAPROXEN | 250MG | TABLET | Resolved | 2021-02-26 | 2021-03-24 | 134820 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2019-03-13 | 2019-05-13 | 78536 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2019-03-13 | 2019-05-13 | 78541 |
| APO-NAPROXEN | 375MG | TABLET | Resolved | 2022-09-01 | 2022-11-20 | 168421 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2022-12-16 | 2023-01-20 | 178742 |
| APO-NAPROXEN | 500MG | TABLET | Resolved | 2023-02-23 | 2023-05-06 | 185459 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BROMAZEPAM - TAB 1.5MG | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM - TAB 3MG | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM - TAB 6MG | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |